An Open-Label, Multicenter Phase 2 Study of Lenvatinib (E7080) in Unresectable Biliary Tract Cancer (BTC) Who Failed Gemcitabine-based Combination Chemotherapy

Trial Profile

An Open-Label, Multicenter Phase 2 Study of Lenvatinib (E7080) in Unresectable Biliary Tract Cancer (BTC) Who Failed Gemcitabine-based Combination Chemotherapy

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Dec 2017

At a glance

  • Drugs Lenvatinib (Primary)
  • Indications Biliary cancer; Gallbladder cancer
  • Focus Therapeutic Use
  • Sponsors Eisai Co Ltd
  • Most Recent Events

    • 12 Sep 2017 Interim results presented at the 42nd European Society for Medical Oncology Congress.
    • 31 Aug 2017 According to an Eisai Inc media release, the company will present the new clinical data from this trial at European Society of Medical Oncology (ESMO) 2017.
    • 21 Jan 2017 Interim results (n=17; data cut off: 25 Jul 2016) presented at the 2017 Gastrointestinal Cancers Symposium
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top